Table 1. Characteristics of study subjects.
| HC (n = 23) | CHB (n = 22) | ACLF (n = 51) |
||||
|---|---|---|---|---|---|---|
| Total (n = 51) | Survival (n = 28) | Non-survival (n = 23) | P | |||
| Age (years) | 34.15 ± 4.13 | 45.35 ± 4.51 | 42.86 ± 6.53 | 40.32 ± 4.51 | 46.12 ± 4.22 | NS |
| Male (%) | 12 (52.1%) | 17 (77.2%) | 44 (86.2%) | 24 (85.7%) | 20 (86.9%) | NS |
| HBeAg positive n (%) | / | 12 (54.5%) | 24 (47.1%) | 14 (58.3%) | 10 (41.7%) | NS |
| Log10HBV DNA (IU/mL) | / | 3.78 ± 0.51 | 4.33 ± 0.91 | 4.07 ± 0.33 | 4.97 ± 1.01 | NS |
| Cirrhotic n (%) | / | / | 33 (64.7%) | 19 (67.8%) | 14 (60.8%) | NS |
| TB (μmol/L) | 10.12 ± 0.21 | 36.67 ± 3.41 | 380.67 ± 32.76 | 340.23 ± 22.45 | 440.19 ± 39.08 | <0.05 |
| INR | / | 0.99 ± 0.07 | 2.01 ± 0.41 | 1.89 ± 0.31 | 2.39 ± 0.67 | <0.05 |
| ALT (IU/L) | 21.37 ± 4.45 | 114.27 ± 22.45 | 386.13 ± 39.24 | 296.13 ± 37.25 | 500.13 ± 46.65 | <0.05 |
| Albumin (g/L) | 45.37 ± 2.75 | 39.67 ± 6.55 | 26.69 ± 3.87 | 29.33 ± 4.67 | 24.69 ± 5.82 | NS |
| BPC (×109) | / | 201.87 ± 22.75 | 99.17 ± 9.75 | 113.47 ± 20.15 | 83.42 ± 25.65 | NS |
| Cre (mg/dL) | / | 0.97 ± 0.13 | 1.25 ± 0.21 | 1.34 ± 0.19 | 1.22 ± 0.31 | NS |
| MELD score | / | / | 2.88 ± 1.19 | 2.72 ± 1.01 | 3.21 ± 1.47 | <0.05 |
| SOFA score | / | / | 7.18 ± 2.99 | 5.61 ± 1.72 | 9.00 ± 2.98 | <0.05 |
Data are presented as values (percentage) or mean ± SD. Abbreviations: HC, healthy controls; CHB, chronic hepatitis B; ACLF, acute-on-chronic liver failure; HBeAg, hepatitis Be antigen; TB, total bilirubin; INR, international normalized ratio; BPC, blood platelet counts; Cre, Creatinine; MELD score, model for the end-stage liver disease score; SOFA score, sepsis-related organ failure assessment score; NS, not significant. *P values correspond to the comparison of the Survival and Non-survival groups of HBV-ACLF patients.